Agency: European Commission | Branch: FP7 | Program: CSA-SA | Phase: ENERGY-2007-2.5-02 | Award Amount: 999.96K | Year: 2008
The growing economies in the southern and eastern Mediterranean area increasingly need affordable and efficient energy and water for sustainable development. Hybrid solar/fossil thermal power plants with combined sea water desalination based on concentrating solar power technology (CSP) offer a unique, cost efficient solution to the growing energy and water demand. Hybrid solar/fossil operation offers a smooth transition from the fossil fuel to a solar economy and provides firm power capacity to the grid with up to 8000 full load operating hours per year. The main objective of the MED CSD project is the assessment of the technico-economic potential of CSP for electricity and desalination in Mediterranean region, particularly the Mediterranean Partners Countries (MPCs) (WP3) based on a technology review and considering the results of past and on-going studies and projects (Aqaba project as a reference) (WP1) and attained through the realization of feasibility studies in Mediterranean countries and an impact assessment analysis (WP2). WP1 is the selection of CSP and desalination configurations suitable for application in the Southern and Eastern Mediterranean region, using information on state of the art of CSP and desalination, specifically engineering performed for Aqaba hybrid CSP desalination plant, and taking into consideration the specific situation and needs where the feasibility studies will be performed. In WP2, a generic feasibility study will be defined and applied to Algeria, Italian Island, Egypt, Morocco and PNA including an impact assessment analysis for a broad dissemination. WP3 will relate to the assessment of the technico-economic potential of CSP for electricity and desalination in Mediterranean Partner Countries (MPCs). It will be followed by an Action Plan and dissemination of the results (WP4).
Agency: European Commission | Branch: FP7 | Program: CSA-SA | Phase: INCO.2011-6.2 | Award Amount: 548.00K | Year: 2012
The overarching aim of the J-ERAcenter is: To contribute to the effective integration of Jordan into ERA, through building the National Centre for Research and Development (NCRD) organisational, strategic and human capacities to actively participate in European S&T partnerships and execute large-scale projects in the key area of Renewable Energy, with a view to creating a centre of excellence within Jordan and actively promoting further dissemination and replication in the region. Specifically J-ERAcenter aims: To build capacities in international R&D cooperation and EU project management, by providing targeted training to NCRD staff and researchers and enable them to replicate the knowledge benefiting a wider target group of researchers in Jordan. To strengthen direct links between research teams of NCRD and their EU counterparts and initiate joint R&D initiatives in the area of Renewable Energy, through a series of networking/partnering events and facilitating mobility of researchers. To ensure firm and sustainable implementation of the enhanced capacities at NCRD with a view to promoting the centres international competitiveness and improve its response to socio-economic challenges; through implementing specific internationalisation, visibility, IP and competitiveness strategies (for enhancement of the institutional development strategy), and the implementation of a R&D Cooperation Unit. To promote the visibility and impact of this pilot action, positioning NCRD as a Centre of Excellence for EU-Jordan RTD cooperation, via targeted multiplication and dissemination actions (networking events, info-days, seminars). Jordans leading research centre in Renewable Energy is the main beneficiary and coordinator, due to its high multiplier potential to act as catalyst for integration into ERA, and the importance of RE to both regions. The consortium includes EU partners with complementary expertise in the scientific field (UASTV, UMU) and EU project management (UA).
News Article | November 1, 2016
TORONTO, ON--(Marketwired - Oct 31, 2016) - Helix BioPharma Corp. (TSX: HBP) ( : HBP), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the year ended July 31, 2016. The Company recorded a net loss and total comprehensive loss of $9,665,000 and $8,730,000 (a loss per common share of $0.11 and $0.11) for the fiscal years ended July 31, 2016 and 2015 respectively. Research and development costs totalled $5,821,000 and $4,885,000, respectively for the twelve periods ended July 31, 2016 and July 31, 2015. Research and development expenses for the year ended July 31, 2016 when compared to the year ended July 31, 2015 were impacted by higher contract research organization costs related to the European Phase I/II clinical study in Poland and costs associated with the Phase I clinical trial of LDOS001 in the U.S. but were offset by lower contract manufacturing expenditures in the current year. The Company paid an amount to the consulting group involved in the Company's successful qualification for grant money from the Polish National Center for Research and Development. Operating, general and administration expenses for the years ended July 31, 2016 and July 31, 2015 totalled $3,836,000 and $3,892,000 respectively). Consulting services fees decreased in fiscal 2016, primarily as a result of factors related to Helix's termination of several third-party consultants. This decrease was partially offset higher costs relating to senior management change overs. The Company's cash reserves of $3,654,000, as at July 31, 2016, are insufficient to meet anticipated cash needs for working capital and capital expenditures through the next twelve months, nor are they sufficient to see the current research and development initiatives through to completion. Management therefore considers securing additional funds, expected to be through the issuance of equity securities of the Company, to be of the utmost importance. The Company's Consolidated Statement of Financial Position as at July 31, 2016 and July 31, 2015 are summarized below. The Company's Consolidated Statements of Net Loss and Comprehensive Loss and Consolidated Statements of Cash Flow for fiscal 2016 and 2015 are summarized below: The Company's condensed unaudited interim consolidated financial statements and management's discussion and analysis will be filed under the Company's profile on SEDAR at www.sedar.com, as well as on the Company's website at www.helixbiopharma.com. Shareholders have the ability to receive a hard copy of the Company's unaudited condensed interim consolidated financial statements free of charge upon request at the address below. About Helix BioPharma Corp. Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate. Helix is currently listed on the TSX and FSE under the symbol "HBP". Forward-Looking Statements and Risks and Uncertainties This news release contains forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include financial projections and estimates, statements regarding plans, goals, objectives, intentions and expectations with respect to the Company's future business, operations, research and development, including the Company's activities relating to DOS47, and other information in future periods. Forward-looking statements include, without limitation, statements concerning (i) the Company's ability to operate on a going concern being dependent mainly on obtaining additional financing; (ii) the Company's priority continuing to be L-DOS47; (iii) the Company's development programs for DOS47 and L-DOS47; (iv) future expenditures, the insufficiency of the Company's current cash resources and the need for financing; and (v) future financing requirements and the seeking of additional funding. Forward-looking statements can further be identified by the use of forward-looking terminology such as "ongoing", "estimates", "expects", or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions "will", "may", "could", or "should" occur or be achieved, or comparable terminology referring to future events or results. Forward-looking statements are statements about the future and are inherently uncertain, and are necessarily based upon a number of estimates and assumptions that are also uncertain. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Forward-looking statements, including financial outlooks, are intended to provide information about management's current plans and expectations regarding future operations, including without limitation, future financing requirements, and may not be appropriate for other purposes. Certain material factors, estimates or assumptions have been applied in making forward-looking statements in this news release, including, but not limited to, the safety and efficacy of L-DOS47; that sufficient financing will be obtained in a timely manner to allow the Company to continue operations and implement its clinical trials in the manner and on the timelines anticipated; the timely provision of services and supplies or other performance of contracts by third parties; future costs; the absence of any material changes in business strategy or plans; and the timely receipt of required regulatory approvals and strategic partner support. The Company's actual results could differ materially from those anticipated in the forward-looking statements contained in this news release as a result of numerous known and unknown risks and uncertainties, including without limitation, the risk that the Company's assumptions may prove to be incorrect; the risk that additional financing may not be obtainable in a timely manner, or at all, and that clinical trials may not commence or complete within anticipated timelines or the anticipated budget or may fail; third party suppliers of necessary services or of drug product and other materials may fail to perform or be unwilling or unable to supply the Company, which could cause delay or cancellation of the Company's research and development activities; necessary regulatory approvals may not be granted or may be withdrawn; the Company may not be able to secure necessary strategic partner support; general economic conditions, intellectual property and insurance risks; changes in business strategy or plans; and other risks and uncertainties referred to elsewhere in this news release, any of which could cause actual results to vary materially from current results or the Company's anticipated future results. Certain of these risks and uncertainties, and others affecting the Company, are more fully described in Helix's Annual Information Form, in particular under the headings "Forward-looking Statements" and "Risk Factors", and other reports filed under the Company's profile on SEDAR at www.sedar.com from time to time. Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix's management on the date of this new release, and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required by law.
Al-Beitawi N.A.,Jordan University of Science and Technology |
Momani Shaker M.,Czech University of Life Sciences |
El-Shuraydeh K.N.,National Center for Research and Development |
Blaha J.,Czech University of Life Sciences
Journal of Applied Animal Research | Year: 2016
The study objective was to investigate the effect of three levels of nanoclay minerals (1%, 1.5% and 2%) on growth performance, internal organs and blood biochemistry of broiler chickens compared to vaccines and antibiotics. An experiment of nine dietary treatments was conducted for over than 36 days. Groups 1, 2 and 3 were fed diet without nanoclay minerals and served as control group (positive with vaccines and antibiotics (C1), positive with vaccines only (C2) and negative without any of them (C3). Treatments groups 1, 2, 3, 4, 5 and 6 were fed the same diet with the above-mentioned levels once a week or once in 2 weeks. 2% nanoclay minerals fed at the two intervals significantly improved broilers’ performance in terms of live body weight, body weight gain and feed conversion ratio compared to control groups. Concerning blood biochemistry, high-density lipoprotein which known to be beneficial for humans increased (P < .05) by feeding 1.5% nanoclay minerals at the two ages compared to control groups and other treatments. In conclusion, the present results indicate that nanoclay minerals in particular levels and doses improve the growth performance of broiler chickens. Nanotechnology as a new tool has the potential to improve broiler production. © 2016 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
Skurzynski P.,National Center for Research and Development |
Bociag K.,University of Gdansk
Phycologia | Year: 2011
Studies on the germination of charophyte oospores in lake populations have revealed that oospores germinate rarely and in small numbers. Despite this, perennial populations of charophytes continue to exist in deep lakes in Poland. We examined the reproductive potential of vegetative parts of charophyte thallus to determine how these might contribute to charophyte persistence. Thallus fragments of Chara rudis can form a propagule bank and function as vegetative propagules that give rise to new thalli (ramets) in Polish lakes. Experimental results show that naturally produced thallus fragments are present on the benthic sediment surface and can initiate new growth, resulting in new plants. Multinode fragments and apical fragments produce the largest number of ramets. Thallus fragments from the deep zones (> 5 m) produce the more ramets than those from shallower areas. Thus, thallus fragments play a significant role in population persistence in the deep areas of the lake. Given the reported low germination rates of oospores from perennial populations, it is likely that vegetative reproduction, via thallus fragments, has an important role in population maintenance.
Elshuraydeh K.N.,National Center for Research and Development |
Al-Beitawi N.A.,Jordan University of Science and Technology |
Al-Faqieh M.A.,National Center for Research and Development
Journal of Nanotechnology in Engineering and Medicine | Year: 2014
The effect of using different concentrations of aqueous nanosuspensions of clay minerals (1%, 1.5%, and 2%) offered at different periods of time (one time per one or two weeks) compared with tap-water with and without antibiotics on growth performance and some selected antibody titer was studied. The experiment lasted from 1 to 36 days of age. The statistical findings of the experiment prove that aqueous nanosuspension 1% offered one time per two weeks significantly improved feed conversion ratio (FCR). Meanwhile, aqueous nanosuspension 2% offered one time per two weeks significantly gave the same effect on live body weight (LBW) and body weight gain (BWG) as did antibiotics. Concerning the findings that pertain to immunity, antibody titer against the most infectious diseases [Newcastle (ND), infectious bronchitis (IB), and infectious bursal disease (IBD)] were significantly improved by offering aqueous nanosuspension 1.5% offered one time per one and two weeks, and aqueous nanosuspension 1% offered one time per one week, respectively. Copyright © 2014 by ASME.
Mohammed L.B.,Al-Zaytoonah University of Jordan |
Hamdan M.A.,Al-Zaytoonah University of Jordan |
Abdelhafez E.A.,Al-Zaytoonah University of Jordan |
Shaheen W.,National Center for Research and Development
Jordan Journal of Mechanical and Industrial Engineering | Year: 2013
In this study, Nonlinear Autoregressive Exogenous (NARX) model was used to predict hourly solar radiation in Amman, Jordan. This model was constructed and tested using MATLAB software. The performance of NARX model was examined and compared with different training algorithms. Meteorological data for the years from 2004 to 2007 were used to train the Artificial Neural Network (ANN) while the data of the year 2008 were used to test it. The Marquardt-Levenberg learning algorithm with a minimum root mean squared error (RMSE) and maximum coefficient of determination (R) was found as the best in both training and validation period when applied in NARX model. © 2013 Jordan Journal of Mechanical and Industrial Engineering.